

## Profit Participating Loan 2015



### Prenatal Diagnostics at the Highest Level: Risk-Free, Rapid, and Affordable!

The PrenaLab UG will be undertaking a new path in prenatal diagnostics. As a biotech start-up deriving from the Charité University Hospital Berlin, we offer a new, risk-free prenatal diagnostic test based on biomarker profiles.

Currently, we are in the phase of prototype evaluation and have initiated design of the final product, a diagnostic kit. This test can be performed in every genetic diagnostic laboratory, and due to software specifically designed for the test, the results will be evaluated and medically reported.

The product falls under the medical device directive of the European Union and requires CE marking as an in-vitro diagnostic test.

The launch of the product is planned for 2016/17 and the assay will be distributed worldwide through existing channels.

In parallel with the development of the test, initial talks with experienced distribution partners and preparation of international registrations has been initiated.

For the further expansion of our business, PrenaLab UG allocates profit participating loans, to enter the market product within a minimum amount of time.

For further questions, please do not hesitate to contact me.

Dr. Martin Burow, Managing director PrenaLab UG  
(haftungsbeschränkt),  
Barfusstrasse, 14, D-13349 Berlin, Germany  
Tel.: +49-3322-4248997, Fax: +49 3322 4248729  
Mobile: +49-172-3205601  
Internet: [www.PrenaLab.com](http://www.PrenaLab.com)  
Email: [M.Burow@prenalab.com](mailto:M.Burow@prenalab.com)

#### The investment offer in 2015 at a glance

|                    |                                                                                                                                     |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Loan               | Profit participating loan (junior loan)                                                                                             |
| Return             | 7.5%/annum following generation of positive cash flow, payable at the end of term plus 7.5%/annum when targets are met (see exposé) |
| Term               | 5 years                                                                                                                             |
| Minimum investment | € 2500 and multiples                                                                                                                |

#### Your advantages

- Investment in an easy to understand market
- Target achievement means profits far beyond existing interest rates
- Clear investment duration
- Due to the junior loan, no additional legal and operational liabilities
- Investment is possible, starting from € 2500

#### Further supporters of this project are:

